Literature DB >> 36245663

Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Intensive Care Unit Admission Diagnosis: A Prospective Cohort Study.

Goni Katz-Greenberg1,2, Michael Malinchoc3, Dennis L Broyles3, David Oxman4, Seyed M Hamrahian2, Omar H Maarouf2.   

Abstract

Background: Acute kidney injury (AKI) is most commonly caused by tubular injury and is associated with a wide variety of critical illnesses. It is well known that urinary biomarkers can lead to the early identification of AKI. However, the ability of urinary biomarkers to distinguish between different types of critical illness has been less studied.
Methods: In this prospective cohort study, urinary neutrophil gelatinase-associated lipocalin (uNGAL) was measured in 107 patients consecutively admitted to the ICUs in our tertiary medical center. uNGAL samples were collected within 3-6 hours of admission to an ICU and measured by ELISA. All data were analyzed using R statistical software, and univariate analysis was used to determine the correlations of uNGAL levels with AKI stage, admission diagnoses, and ICU course.
Results: uNGAL level increased by a mean of 24-fold (SD 10-59) in ICU patients with AKI and demonstrated a significant correlation with the different AKI stages. uNGAL predicted the need for RRT, with values increased by more than 15-fold (P<0.05) in patients needing RRT, and remained a useful tool to predict AKI in ICU patients with a urinary tract infection. uNGAL level was correlated with certain ICU admitting diagnoses whereby uNGAL levels were lower in ICU patients with cardiogenic shock compared with other admission diagnoses (β=-1.92, P<0.05). Conclusions: uNGAL can be used as an early predictor of AKI and its severity in patients admitted to the ICU, including the need for RRT. uNGAL may also help in distinguishing patients with cardiogenic shock from those with other critical illnesses and identifying those at risk for poor outcomes irrespective of the presence of AKI.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  AKI; ICU nephrology; NGAL; acute kidney injury; acute kidney injury and ICU nephrology; cardiogenic shock; injury marker; lipocalin-2; sepsis; shock; urine biomarker

Mesh:

Substances:

Year:  2022        PMID: 36245663      PMCID: PMC9528386          DOI: 10.34067/KID.0001492022

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  60 in total

Review 1.  Perspective on Clinical Application of Biomarkers in AKI.

Authors:  Chirag R Parikh; Sherry G Mansour
Journal:  J Am Soc Nephrol       Date:  2017-02-20       Impact factor: 10.121

2.  Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients.

Authors:  Jacob C Jentzer; Patrick R Lawler; Sean van Diepen; Timothy D Henry; Venu Menon; David A Baran; Vladimír Džavík; Gregory W Barsness; David R Holmes; Kianoush B Kashani
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-12-07

3.  Systemic inflammatory response syndrome in patients hospitalized for gastrointestinal bleeding.

Authors:  B Afessa
Journal:  Crit Care Med       Date:  1999-03       Impact factor: 7.598

4.  A Prospective International Multicenter Study of AKI in the Intensive Care Unit.

Authors:  Josée Bouchard; Anjali Acharya; Jorge Cerda; Elizabeth R Maccariello; Rajasekara Chakravarthi Madarasu; Ashita J Tolwani; Xinling Liang; Ping Fu; Zhi-Hong Liu; Ravindra L Mehta
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-20       Impact factor: 8.237

5.  Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults.

Authors:  Edward D Siew; Lorraine B Ware; Tebeb Gebretsadik; Ayumi Shintani; Karel G M Moons; Nancy Wickersham; Frederick Bossert; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

6.  Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis.

Authors:  Christian Albert; Antonia Zapf; Michael Haase; Christian Röver; John W Pickering; Annemarie Albert; Rinaldo Bellomo; Tobias Breidthardt; Fabrice Camou; Zhongquing Chen; Sidney Chocron; Dinna Cruz; Hilde R H de Geus; Prasad Devarajan; Salvatore Di Somma; Kent Doi; Zoltan H Endre; Mercedes Garcia-Alvarez; Peter B Hjortrup; Mina Hur; Georgios Karaolanis; Cemil Kavalci; Hanah Kim; Paolo Lentini; Christoph Liebetrau; Miklós Lipcsey; Johan Mårtensson; Christian Müller; Serafim Nanas; Thomas L Nickolas; Chrysoula Pipili; Claudio Ronco; Guillermo J Rosa-Diez; Azrina Ralib; Karina Soto; Rüdiger C Braun-Dullaeus; Judith Heinz; Anja Haase-Fielitz
Journal:  Am J Kidney Dis       Date:  2020-07-15       Impact factor: 8.860

7.  Duration of acute kidney injury and mortality in critically ill patients: a retrospective observational study.

Authors:  Seung Seok Han; Sejoong Kim; Shin Young Ahn; Jeonghwan Lee; Dong Ki Kim; Ho Jun Chin; Dong-Wan Chae; Ki Young Na
Journal:  BMC Nephrol       Date:  2013-06-27       Impact factor: 2.388

8.  The clinical utility window for acute kidney injury biomarkers in the critically ill.

Authors:  Azrina Md Ralib; John W Pickering; Geoffrey M Shaw; Martin P Than; Peter M George; Zoltán H Endre
Journal:  Crit Care       Date:  2014-11-04       Impact factor: 9.097

9.  Correction: Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis.

Authors:  Amay Parikh; John A Rizzo; Pietro Canetta; Catherine Forster; Meghan Sise; Omar Maarouf; Eugenia Singer; Antje Elger; Saban Elitok; Kai Schmidt-Ott; Jonathan Barasch; Thomas L Nickolas
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

10.  Duration of acute kidney injury in critically ill patients.

Authors:  Christine K Federspiel; Theis S Itenov; Kala Mehta; Raymond K Hsu; Morten H Bestle; Kathleen D Liu
Journal:  Ann Intensive Care       Date:  2018-02-23       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.